This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McKeating, J A Articles by Balfe, P Search for Related Content PubMed PubMed Citation Articles by McKeating, J A Articles by Balfe, P

 Previous Article  |  Next Article 

J Virol. 1993 September; 67(9): 5216-5225

Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom.

ABSTRACT

We have selected an HXB2 variant which can replicate in the presence of a neutralizing human serum. Sequencing of the gp120 region of the env gene from the variant and parental viruses identified a single amino acid substitution in the third conserved region of gp120 at residue 375 (AGT-->AAT, Ser-->Asn; designated 375 S/N). The escape mutant was found to be resistant to neutralization by soluble CD4 (sCD4) and four monoclonal antibodies (MAbs), 39.13g, 1.5e, G13, and 448, binding to epitopes overlapping that of the CD4 binding site (CD4 b.s.). Introduction of the 375 S/N mutation into HXB2 by site-directed mutagenesis confirmed that this mutation is responsible for the neutralization-resistant phenotype. Both sCD4 and three of the CD4 b.s. MAbs (39.13g, 1.5e, and G13) demonstrated reduced binding to the native 375 S/N mutant gp120. The ability to select for an escape variant resistant to multiple independent CD4 b.s. MAbs by a human serum confirms the reports that antibodies to the discontinuous CD4 b.s. are a major component of the group-specific neutralizing activity in human sera.

This article has been cited by other articles:

• Liu, X., Lagenaur, L. A., Lee, P. P., Xu, Q. (2008). Engineering of a Human Vaginal Lactobacillus Strain for Surface Expression of Two-Domain CD4 Molecules. Appl. Environ. Microbiol. 74: 4626-4635 [Abstract] [Full Text]  
• Chien, P. C. Jr., Cohen, S., Tuen, M., Arthos, J., Chen, P.-d., Patel, S., Hioe, C. E. (2004). Human Immunodeficiency Virus Type 1 Evades T-Helper Responses by Exploiting Antibodies That Suppress Antigen Processing. J. Virol. 78: 7645-7652 [Abstract] [Full Text]  
• Beaumont, T., Quakkelaar, E., van Nuenen, A., Pantophlet, R., Schuitemaker, H. (2004). Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker. J. Virol. 78: 5651-5657 [Abstract] [Full Text]  
• Chang, T. L.-Y., Chang, C.-H., Simpson, D. A., Xu, Q., Martin, P. K., Lagenaur, L. A., Schoolnik, G. K., Ho, D. D., Hillier, S. L., Holodniy, M., Lewicki, J. A., Lee, P. P. (2003). Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl. Acad. Sci. USA 100: 11672-11677 [Abstract] [Full Text]  
• Hammond, A. L., Lewis, J., May, J., Albert, J., Balfe, P., McKeating, J. A. (2001). Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization. J. Virol. 75: 5593-5603 [Abstract] [Full Text]  
• Lewis, J., Balfe, P., Arnold, C., Kaye, S., Tedder, R. S., McKeating, J. A. (1998). Development of a Neutralizing Antibody Response during Acute Primary Human Immunodeficiency Virus Type 1 Infection and the Emergence of Antigenic Variants. J. Virol. 72: 8943-8951 [Abstract] [Full Text]  
• Cecilia, D., KewalRamani, V. N., O'Leary, J., Volsky, B., Nyambi, P., Burda, S., Xu, S., Littman, D. R., Zolla-Pazner, S. (1998). Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage. J. Virol. 72: 6988-6996 [Abstract] [Full Text]